ReadyCell

ReadyCell offers Pre-plated Permeability Assays with Caco-2, HT-29, and MDCKII cells to facilitate the investigation of compound absorption across relevant barriers. This aids in determining a compound’s suitability for oral dosing, a critical step in drug development.

Analysing the permeability of compounds across a cell monolayer is a widely recognised in vitro method for assessing oral absorption and investigating transport mechanisms. The range of pre-plated transwell products ensures rapid and accurate determination of drug transport across Caco-2, HT-29, and MDCKII cell monolayers.

Blood Brain Barrier (BBB) Assays

ReadyCell’s Blood Brain Barrier (BBB) Assays enable researchers to conduct a thorough assessment of the permeability and intricate transporter-drug interactions. The kits offer a valuable tool to assist researchers in determining the suitability of their compounds for BBB traversal.

To gain insights into the pharmacological route and enhance clinical stages, it is recommended to assess the interaction of in-development molecules with P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP) receptors. ReadyCell’s suite of assay-based plates, including CacoReady, PreadyPort MDR1, and PreadyPort BCRP, facilitates the identification of whether new molecular entities serve as substrates or inhibitors of MDR1 or BCRP, thereby aiding in the refinement of drug candidates.

In Vitro Cytotoxicity Assays

ReadyCell’s innovative ready-to-use cell-based plates offer a superior alternative to traditional colorimetric assays. The CacoReady plates enable the identification of potential toxicity at early research stages. Utilising CacoReady researchers can accurately predict and stratify intestinal compound toxicity by evaluating the transepithelial electrical resistance (TEER) value and the lucifer yellow (LY) paracellular flux, two crucial indicators of cell barrier integrity.

CacoReady is a pre-plated transwell product that contains Caco-2 cells, which are human intestinal epithelial cells. Since Caco-2 cells resemble the human intestinal epithelium more closely than other cell lines or animal models, it provides a more relevant and reliable model for intestinal drug studies. Short-term cytotoxicity tests frequently yield positive results that correlate effectively with short-term in vivo implantation tests. Therefore, utilising CacoReady can reduce the need for animal testing, lowers costs, and speeds up the development of new drugs.

Moreover, for traditional studies, ReadyCell also offers plates without transwell inserts, catering to a wider range of research needs and methodologies.

Transporter Kits for Drug-Drug Interactions (DDI) Studies

ReadyCell offers a range of ready-to-use Efflux Transporter Kits and Uptake Transporter Plates that are indispensable tools for studying drug-drug interactions (DDI) and optimising drug discovery screening. They offer a highly predictive in vitro model, aligning with FDA and EMA guidelines for robust DDI assessment.

Ready to use Efflux Transporter Plates

About ReadyCell

ReadyCell is a leading biotechnology company delivering innovative rapidly deployable cell-based in vitro products and tools that accelerate drug discovery.

The company’s groundbreaking cell-based ready-to-use ADME-Tox kits are utilised by leading pharmaceutical, biotechnology, academic, and contract research organisations worldwide to optimise the development cycle for new drugs.

With more than a decade of experience, ReadyCell has developed a revolutionary medium for the transportation of live plated cells preserving their full viability and cellular attributes, to ensure highly reliable results whilst improving time and cost efficiency.

Headquartered at Barcelona Science Park, ReadyCell has established a wide distribution network enabling researchers and scientists around the world to access the most innovative tools for all their in vitro ADME-Tox, DMPK, and DDI studies.